{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:41:38Z","timestamp":1779324098098,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40265-015-0408-8","type":"journal-article","created":{"date-parts":[[2015,5,18]],"date-time":"2015-05-18T08:33:49Z","timestamp":1431938029000},"page":"899-910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Liraglutide: A Review of Its Use in the Management of Obesity"],"prefix":"10.1007","volume":"75","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,19]]},"reference":[{"key":"408_CR1","unstructured":"World Health Organization. Obesity and overweight: fact sheet no. 311. 2014. http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/ . Accessed 22 Jan 2015."},{"key":"408_CR2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.","journal-title":"BMC Public Health."},{"issue":"16","key":"408_CR3","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","volume":"346","author":"P Angulo","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221\u201331.","journal-title":"N Engl J Med."},{"issue":"5","key":"408_CR4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/oby.20394","volume":"21","author":"GA Bray","year":"2013","unstructured":"Bray GA. Why do we need drugs to treat the patient with obesity? Obesity. 2013;21(5):893\u20139.","journal-title":"Obesity."},{"key":"408_CR5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"Lancet Prospective Studies Collaboration","year":"2009","unstructured":"Collaboration Lancet Prospective Studies, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083\u201396.","journal-title":"Lancet."},{"issue":"25 Pt B","key":"408_CR6","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","volume":"63","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2985\u20133023.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"408_CR7","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/1359105312451865","volume":"18","author":"F Wright","year":"2013","unstructured":"Wright F, Boyle S, Baxter K, et al. Understanding the relationship between weight loss, emotional well-being and health-related quality of life in patients attending a specialist obesity weight management service. J Health Psychol. 2013;18(4):574\u201386.","journal-title":"J Health Psychol."},{"issue":"5","key":"408_CR8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5665\/sleep.2618","volume":"36","author":"ST Kuna","year":"2013","unstructured":"Kuna ST, Reboussin DM, Borradaile KE, et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. Sleep. 2013;36(5):641\u20139.","journal-title":"Sleep."},{"key":"408_CR9","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11883-014-0445-x","volume":"16","author":"JO Ebbert","year":"2014","unstructured":"Ebbert JO, Elrashidi MY, Jensen MD. Managing overweight and obesity in adults to reduce cardiovascular disease risk. Curr Atheroscler Rep. 2014;16:445.","journal-title":"Curr Atheroscler Rep."},{"key":"408_CR10","unstructured":"National Institute for Health and Care Excellence. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. Partial update of CG43. 2014. http:\/\/www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0071374\/ . Accessed 20 Feb 2014."},{"key":"408_CR11","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40618-014-0137-y","volume":"37","author":"G Muscogiuri","year":"2014","unstructured":"Muscogiuri G, Cignarelli A, Giorgino F, et al. GLP-1: benefits beyond pancreas. J Endocrinol Invest. 2014;37:1143\u201353.","journal-title":"J Endocrinol Invest."},{"key":"408_CR12","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/ijo.2012.208","volume":"37","author":"JJ Holst","year":"2013","unstructured":"Holst JJ. Incretin hormones and the satiation signal. Int J Obesity. 2013;37:1161\u20138.","journal-title":"Int J Obesity."},{"issue":"1","key":"408_CR13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/dom.12119","volume":"16","author":"S Madsbad","year":"2014","unstructured":"Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapuetic implications. Diabetes Obes Metab. 2014;16(1):9\u201321.","journal-title":"Diabetes Obes Metab."},{"issue":"17","key":"408_CR14","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1517\/14656566.2014.965678","volume":"15","author":"EW Iepsen","year":"2014","unstructured":"Iepsen EW, Torekov SS, Holst JJ. Therapies for inter-relating diabetes and obesity: GLP-1 and obesity. Expert Opin Pharmacother. 2014;15(17):2487\u2013500.","journal-title":"Expert Opin Pharmacother."},{"issue":"6","key":"408_CR15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diab.45.6.832","volume":"45","author":"C \u00d8rskov","year":"1996","unstructured":"\u00d8rskov C, Poulsen SS, Moller M, et al. Glucagon-like peptide 1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes. 1996;45(6):832\u20135.","journal-title":"Diabetes."},{"issue":"10","key":"408_CR16","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473\u201388.","journal-title":"J Clin Invest."},{"issue":"18","key":"408_CR17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s40265-014-0321-6","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Liraglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(18):2161\u201374.","journal-title":"Drugs."},{"key":"408_CR18","unstructured":"Novo Nordisk. Saxenda\u00ae liragluitde (rDNA) injection: US prescribing information. 2014. http:\/\/www.saxenda.com\/ . Accessed 21 Jan 2014."},{"issue":"4","key":"408_CR19","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","volume":"155","author":"C Pyke","year":"2014","unstructured":"Pyke C, Heller RS, Kirk RK, et al. GLP-1 localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280\u201390.","journal-title":"Endocrinology."},{"issue":"2","key":"408_CR20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diabres.2012.02.016","volume":"97","author":"M Horowitz","year":"2012","unstructured":"Horowitz M, Flint A, Jones KL, et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(2):258\u201366.","journal-title":"Diabetes Res Clin Pract."},{"issue":"6","key":"408_CR21","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J Can Van","year":"2014","unstructured":"Van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38(6):784\u201393.","journal-title":"Int J Obes."},{"key":"408_CR22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1475-2840-10-109","volume":"10","author":"K Inoue","year":"2011","unstructured":"Inoue K, Maeda N, Kashine S, et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:109.","journal-title":"Cardiovasc Diabetol."},{"key":"408_CR23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1475-2840-11-107","volume":"11","author":"Y Fujishima","year":"2012","unstructured":"Fujishima Y, Maeda N, Inoue K, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;11:107.","journal-title":"Cardiovasc Diabetol."},{"issue":"12","key":"408_CR24","first-page":"1163","volume":"11","author":"J Jendle","year":"2009","unstructured":"Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Antimicrob Agents Chemother. 2009;11(12):1163\u201372.","journal-title":"Antimicrob Agents Chemother."},{"key":"408_CR25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2840-13-36","volume":"13","author":"CJ Li","year":"2014","unstructured":"Li CJ, Yu Q, Yu P, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:36.","journal-title":"Cardiovasc Diabetol."},{"key":"408_CR26","unstructured":"European Medicines Agency. Saxenda: summary of product characteristics. 2015. http:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h992.htm#EndOfPage . Accessed 26 Mar 2015."},{"issue":"9701","key":"408_CR27","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double- blind, placebo-controlled study. Lancet. 2009;374(9701):1606\u201316.","journal-title":"Lancet."},{"issue":"11","key":"408_CR28","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443\u201351.","journal-title":"Int J Obes."},{"key":"408_CR29","unstructured":"Pi-Sunyer FX, Astrup A, Fujioka K, et al. Liraglutide 3.0\u00a0mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight and obese adults: results from Scale Obesity and Prediabetes, a randomized, double-blind and placebo-controlled 56-week trial [abstract no. SAT-0925]. Endocr Rev. 2014;35(3 Suppl)."},{"issue":"1 Suppl 1","key":"408_CR30","first-page":"S38","volume":"57","author":"R DeFronzo","year":"2014","unstructured":"DeFronzo R, Bergenstal R, Bode B, et al. Effect of liraglutide 3.0 mg cessation on efficacy and safety\/tolerability after 56 weeks\u2019 treatment in obese\/overweight adults with type 2 diabetes: SCALE Diabetes [abstract no. 76]. Diabetologia. 2014;57(1 Suppl 1):S38\u20139.","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"408_CR31","first-page":"15","volume":"7","author":"JPH Wilding","year":"2014","unstructured":"Wilding JPH, Astrup A, Fujioka K, et al. Efficacy and safety of liraglutide 3.0\u00a0mg for weight management in overweight and obese adults: the SCALE Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial [abstract no. T4:RS2.3]. Obes Facts. 2014;7(Suppl 1):15.","journal-title":"Obes Facts."},{"key":"408_CR32","unstructured":"Wilding J, Astrup A, Fujioka K, et al. Liraglutide 3.0\u00a0mg improves insulin secretion and action in overweight and obese adults without diabetes: results from Scale Obesity and Prediabetes, a randomized, double-blind and placebo-controlled 56-week trial [abstract no. SAT-0931]. Endocr Rev. 2014;35(3 Suppl)."},{"key":"408_CR33","unstructured":"Pi-Sunyer X, Fujioka K, Le Roux C, et al. Liraglutide 3.0\u00a0mg reduces the prevalence of prediabetes and delays onset of type 2 diabetes in overweight\/obese adults: the SCALE Obesity and Prediabetes trial [abstract no. 73]. Diabetologia. 2014;57(1 Suppl 1):S37."},{"issue":"Suppl 1","key":"408_CR34","first-page":"71","volume":"32","author":"J Wilding","year":"2015","unstructured":"Wilding J, Astrup A, Fujioka K, et al. In overweight and obese adults, liraglutide 3.0\u00a0mg reduces the prevalence of pre-diabetes and delays the onset of type 2 diabetes: SCALE obesity and pre-diabetes trial [abstract no. P134]. Diabet Med. 2015;32(Suppl 1):71.","journal-title":"Diabet Med."},{"key":"408_CR35","unstructured":"Bode B, DeFronzo R, Bergenstal R, et al. Effect of liraglutide 3.0\/1.8\u00a0mg on body weight and cardiometabolic risk factors in overweight\/obese adults with type 2 diabetes: SCALE Diabetes randomised, double-blind, 56-week trial [abstract no. 181]. Diabetologia. 2014;57(1 Suppl 1):S83."},{"key":"408_CR36","unstructured":"Novo Nordisk. FDA briefing document NDA 206321: liraglutide injection, 3\u00a0mg. 2014. http:\/\/www.fda.gov . Accessed 28 Jan 2014."},{"key":"408_CR37","doi-asserted-by":"crossref","unstructured":"Blackman A, Foster G, Zammit G, et al. Liraglutide 3.0\u00a0mg reduces severity of obstructive sleep apnoea and body weight in obese individuals with moderate or severe disease: SCALE Sleep Apnoea trial [abstract no. 184]. Diabetologia. 2014;57(1 Suppl 1):S85.","DOI":"10.1016\/j.sleep.2015.02.058"},{"issue":"6","key":"408_CR38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2\u00a0years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36(6):843\u201354.","journal-title":"Int J Obes."},{"issue":"6","key":"408_CR39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2337\/dc07-9921","volume":"30","author":"S Klein","year":"2007","unstructured":"Klein S, Allison DB, Heymsfield SB, et al. Waist circumference and cardiometabolic risk. A consensus statement for shaping America\u2019s health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 2007;30(6):1647\u201352.","journal-title":"Diabetes Care."},{"key":"408_CR40","doi-asserted-by":"crossref","unstructured":"Davies MJ, Bergenstal R, Bode B, et al. Liraglutide 3.0\u00a0mg for weight management in obese\/overweight adults with type 2 diabetes: SCALE Diabetes 56-week randomised, double-blind, placebo-controlled trial [abstract no. 39]. Diabetologia. 2014(1 Suppl 1):S22\u2013S3.","DOI":"10.1055\/s-0035-1556576"},{"key":"408_CR41","unstructured":"Le Roux C, Lau DCW, Astrup A, et al. Safety and tolerability of liraglutide 3.0\u00a0mg in overweight and obese adults: the SCALE obesity and prediabetes randomised trial [abstract no. 833]. Diabetologia. 2014;57(1 Suppl 1):S338."},{"issue":"3","key":"408_CR42","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1210\/jc.2010-2318","volume":"96","author":"L Hegedus","year":"2011","unstructured":"Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96(3):853\u201360.","journal-title":"J Clin Endocrinol Metab."},{"key":"408_CR43","unstructured":"Health News Network. Health Canada approves Saxenda\u00ae (liraglutide) for the treatment of chronic weight management. 2015. http:\/\/www.chrgonline.com . Accessed 20 Mar 2015."},{"key":"408_CR44","first-page":"2391","volume":"8","author":"S Barja-Fernandez","year":"2014","unstructured":"Barja-Fernandez S, Leis R, Casanueva FF, et al. Drug devlopment strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss. Drug Design Dev Therapy. 2014;8:2391\u2013400.","journal-title":"Drug Design Dev Therapy."},{"key":"408_CR45","unstructured":"FDA. FDA approves weight-management drug Contrave. 2014. http:\/\/www.fda.gov . Accessed 20 Mar 2015."},{"key":"408_CR46","unstructured":"European Medicines Agency. Mysimba 8\u00a0mg\/90\u00a0mg prolonged release tablets: summary of product characteristics. 2015. http:\/\/www.ema.europa.eu . Accessed 20 Apr 2015."},{"issue":"9","key":"408_CR47","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMp1314078","volume":"370","author":"AG Egan","year":"2014","unstructured":"Egan AG, Blind E, Dunder K, et al. Pancreatic safety and incretin-based drugs: FDA and EMA assessment. N Engl J Med. 2014;370(9):794\u20137.","journal-title":"N Engl J Med."},{"key":"408_CR48","unstructured":"Arena Pharmaceuticals GmbH. Belviq (lorcaserin hydrochloride) tablets, for oral use: US prescribing information. 2012. https:\/\/www.belviq.com\/ . Accessed 16 Feb 2015."},{"key":"408_CR49","unstructured":"Vivus Inc. Qsymia (phentermine and topiramate extended-release) capsules, for oral use: US prescribing information. 2014. http:\/\/qsymia.com\/ . Accessed 16 Feb 2015."},{"key":"408_CR50","unstructured":"Orexigen Therapeutics Inc. Contrave (naltrexone HCl and bupropion HCl) extended-release tablets: US prescribing information. 2014. http:\/\/www.orexigen.com . Accessed 23 Mar 2015."},{"key":"408_CR51","unstructured":"FDA. Part 15: Confidentiality of interim results in cardiovacular outcome safety trials. 2014. http:\/\/www.fda.gov . Accessed 20 Mar 2015."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0408-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0408-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0408-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T06:53:20Z","timestamp":1566716000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0408-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0408-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}